Webinar: Superbugs and Drug Resistance: Challenges in New Antibiotic Discovery
Researchers haven’t discovered a truly novel chemical class of antibiotics in more than 30 years. In that time, drug resistance has become an inexorable consequence of antibiotic use and resistance to old drug classes has reached crisis proportions.
Calls to action from infectious disease professionals and public health organizations continue to grow, and in February the World Health Organization (WHO) published its first list of priority bacterial pathogens in an effort to guide international efforts in drug discovery and development. Mainstream media outlets are reporting these concerns to the general public with articles on drug-resistant so-called “superbugs.”
The failure of modern drug discovery to yield new antibiotics is worthy of study in light of remarkable successes in other therapeutic areas in the same period. Indeed, the time is right to make a careful examination of approaches taken to date and chart a new course with methods that break from convention.
In this webinar the speakers will provide an introduction to the problem of drug resistance and an analysis of the failure modern antibiotic drug discovery to yield new antibiotics.
Key Learning Objectives:
Participants in this webinar will increase their understanding of:
• The problem of antibiotic drug resistance
• The gaps in clinical practice
• The failure of modern drug discovery processes to provide viable candidates for new antibiotics
• How research failures can inform new approaches to antibiotic drug discovery
Originally published at drugdiscovery.nd.edu.